Results 271 to 280 of about 129,283 (392)

Real‐world safety and treatment patterns of subcutaneous IgPro20 for chronic inflammatory demyelinating polyneuropathy: Post‐marketing surveillance in Japan

open access: yesClinical and Experimental Neuroimmunology, EarlyView.
Abstract Objectives IgPro20, a subcutaneous immunoglobulin replacement therapy, is approved in Japan for chronic inflammatory demyelinating polyneuropathy (CIDP). This post‐marketing surveillance study characterized real‐world treatment patterns and safety profile of injection site reactions associated with IgPro20 treatment in Japanese patients with ...
Naoki Terasaka   +4 more
wiley   +1 more source

Azathioprine for people with multiple sclerosis. [PDF]

open access: yesCochrane Database Syst Rev
Ridley B   +5 more
europepmc   +1 more source

Clinical use of immunosuppressants [PDF]

open access: yes, 2005
Fung, JJ   +3 more
core  

Clinical liver transplantation [PDF]

open access: yes, 1969
Brettschneider, L   +5 more
core   +1 more source

Clinical characteristics and treatment outcomes of linear IgA bullous dermatosis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Linear immunoglobulin A (IgA) bullous dermatosis (LABD), also referred to as chronic bullous disease of childhood (CBDC), is characterized by the linear deposition of IgA antibodies within the dermal‐epidermal junction. While dapsone is typically recommended, alternative modalities may be considered based on accessibility, severity, and prior ...
Kristie Mar   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy